TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02390843
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of cyclophosphamide will be fixed at 250 mg/m\^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
Study: NCT02354859
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
Study: NCT05278052
Drug: Standard maintenance therapy as decided by the treating medical oncologist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard maintenance therapy/Observation
Study: NCT04139915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT02696330
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
Study: NCT00507741
Drug: Ertafolide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03781115
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non drug oral placebo capsule will be given as a control
Study: NCT00773955
Drug: R-(-)-gossypol acetic acid
Normalized name: citronellol acetate, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02487940
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
Study: NCT02706847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; Oral
Study: NCT01854606
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Description: a Protein Kinase C Inhibitor
Study: NCT00541905
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
Study: NCT01575873
Drug: Placebo for risendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once a day
Study: NCT01575873
Drug: Risendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once a day
Study: NCT01674933
Drug: Duraphat® Fluoride Varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
Study: NCT01247493
Drug: induction chemotherapy (fludarabine, cytarabine, idarubicin)
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine, cytarabine, idarubicin
Study: NCT04325633
Drug: 1: Naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
Study: NCT04325633
Drug: 2: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT00407784
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03288441
Drug: Hold
Normalized name: Hold DM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hold antithrombotic therapy
Study: NCT03180944
Drug: 1.2% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Study: NCT03180944
Drug: 1.0% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Study: NCT03180944
Drug: 0.8% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Study: NCT03180944
Drug: 0.6% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Study: NCT03180944
Drug: 0.4% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Study: NCT02432651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
Study: NCT01721954
Drug: FOLFOX6m
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04122547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet oral od
Study: NCT02286453
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
Study: NCT02803320
Drug: SPF 50 Y65 110 (BAY 987516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
Study: NCT03827447
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
Study: NCT00649740
Drug: Topamax® Sprinkle Capsule 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg, single dose fasting
Study: NCT00002474
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03288441
Drug: Intermediate dose antithrombotic
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
Study: NCT02975076
Drug: Sanchitongshu
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
Study: NCT02975076
Drug: placebo of Sanchitongshu
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
Study: NCT00664664
Drug: APD125
Approvals — FDA: no, EMA: no, PMDA: no
Description: soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
Study: NCT00664664
Drug: APD125
Approvals — FDA: no, EMA: no, PMDA: no
Description: soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
Study: NCT00664664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: soft gelatin capsule, daily dosing for up to 3 weeks
Study: NCT03503305
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml injection of corticosteroid
Study: NCT01383330
Drug: DW-ES(B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625mg
Study: NCT02888236
Drug: LEO 32731
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00675506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg sub-cutaneous injections once daily for 12 months
Study: NCT00936221
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules, 75mg twice daily
Study: NCT00223210
Drug: PLacebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01500993
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
Study: NCT03452865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (same ml of the study drug)
Study: NCT02574962
Drug: H.P. Acthar® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02745639
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
Study: NCT00936221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01844115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01982396
Drug: ABC Twice Daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01982396
Drug: 3TC Once Daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01982396
Drug: 3TC Twice Daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00038441
Drug: DTI-015
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTI-015 injected through a catheter into center of brain tumor.
Study: NCT00993317
Drug: Placebo of CDP870
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given every 2 weeks until Week22 (SC)
Study: NCT00993317
Drug: CDP870 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
Study: NCT00993317
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly.
Study: NCT02231437
Drug: Berodual®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03448536
Drug: Acetaminophen (Tylenol Extra Strength)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg \*2 caplets, orally, single dose
Study: NCT03566979
Drug: Test naproxen sodium tablet
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 2 test naproxen sodium 220 mg tablets
Study: NCT03566979
Drug: Commercial naproxen sodium tablet
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 2 naproxen sodium 220 mg tablets
Study: NCT03566979
Drug: Commercial naproxen sodium liquid gels capsule
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 2 naproxen sodium 220 mg liquid gel capsules
Study: NCT03566979
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo tablets
Study: NCT00160082
Drug: Xepol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01856517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00455741
Drug: Estradiol infusion
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
Study: NCT05774405
Drug: Climara 0.1Mg/24Hr Transdermal System
Normalized name: Climara 0.1mg/24hr Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estradiol patch is used.
Study: NCT00299195
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 150 mg po bid x 24 weeks
Study: NCT00299195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid x 24 weeks
Study: NCT00482222
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00482222
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00482222
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02737813
Drug: Isobaric marcaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric marcaine 2.2 mL for spinal block
Study: NCT02737813
Drug: Hyperbaric marcaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric marcaine 2.2 mL for spinal block
Study: NCT03876106
Drug: LUT014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT02314351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous form of metoclopramide is in the same appearance with placebo
Study: NCT02314351
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
Study: NCT03297502
Drug: Elidel (pimecrolimus) cream 1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03297502
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00134355
Drug: PTK787
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04147195
Drug: LYS006
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
Study: NCT00582491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally everyday for 16 days
Study: NCT02469883
Drug: Sinotecean
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01867047
Drug: ACE-I Cessation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)
Study: NCT01867047
Drug: ACE-I Continuation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)
Study: NCT02807974
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-3150 1.25 to 2.5, 5mg, orally
Study: NCT00765427
Drug: QLT091001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day repeated dose
Study: NCT01928693
Drug: Vigamox 0.5% Ophthalmic Solution
Normalized name: Vigamox 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
Study: NCT00953147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
Study: NCT02997332
Drug: 5 Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
Study: NCT01175759
Drug: Skin test panel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study: NCT00466609
Drug: Placebo (fluoxetine plus placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus fluoxetine at maximum dosage of 80mg per day
Study: NCT00085462
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03317847
Drug: Bromfenac 0.09 % Ophthalmic Solution
Normalized name: bromfenac 0.09 % Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
Study: NCT03013075
Drug: General Anesthetics
Normalized name: GENERAL ANESTHETICS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02316886
Drug: Optimal Medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00524186
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00524186
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02608736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
Study: NCT03790709
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT03508947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride
Study: NCT02383511
Drug: SMT C1100
Normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
Study: NCT02383511
Drug: SMT C1100
Normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
Study: NCT02383511
Drug: SMT C1100
Normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
Study: NCT02577003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ipragliflozin tablet administered orally
Study: NCT02210819
Drug: Recommended VTE pharmacological treatments according to international guidelines
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine.
Study: NCT01179776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v saline
Study: NCT01179776
Drug: Ilomedin and standard low dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02838537
Drug: Exposure to Triptan
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01227408
Drug: doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
Study: NCT04096573
Drug: LC51-0255
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC51-0255
Study: NCT04096573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00787072
Drug: AZD8075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
Study: NCT00787072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT00747318
Drug: SKP FlutiForm HFA pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.